Abstract: Provided herein are deuterium substituted fumarate derivatives and pharmaceutical compositions comprising deuterium substituted fumarate derivatives. Also provided is a method of treating, prophylaxis, or amelioration of a disease, comprising administering to a subject in need of treatment for the disease an effective amount of a deuterium substituted fumarate derivative or a pharmaceutical composition comprising a deuterium substituted fumarate derivative. In one embodiment, the method is a neurodegenerative disease, such as multiple sclerosis, amyotrophic lateral sclerosis, Parkinson's disease, Huntington's disease, or Alzheimer's disease.
Abstract: Provided herein is a method of treating or preventing a disease or disorder (e.g., MS) in a subject in need thereof, comprising (a) administering to the subject a first dose of a pharmaceutical composition comprising a fumarate agent (e.g., DMF) for a first dosing period; (b) administering a vaccine; and (c) administering to the subject a second dose of the pharmaceutical composition for a second dosing period.
Abstract: A limiter for a dispensing device is provided. The limiter includes a body (20) arranged to mount with at least a portion of a dispensing device (300), and a stop extending from the body. The stop (40) is configured to permit movement a plunger of the dispensing device a predetermined distance in a dispensing direction correlated to a desired volume of medium to be delivered from the dispensing device. The stop is configured to prevent further movement of the plunger in the dispensing direction, thereby limiting the amount of medium delivered from the dispensing device. The dispensing device may be a syringe.
Type:
Grant
Filed:
April 16, 2012
Date of Patent:
August 20, 2019
Assignees:
Biogen MA Inc., SHL Group AB
Inventors:
John Kuczek, Clive Patience, Donovan Quinn, Lucio Giambattista
Abstract: Disclosed herein are antisense compounds and methods for decreasing SOD-1 mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate SOD-1 associated diseases, disorders, and conditions. Such SOD-1 associated diseases include amyotrophic sclerosis (ALS).
Abstract: Provided herein is a method of treating or preventing a disease or disorder (e.g., MS) in a subject in need thereof; comprising (a) administering to the subject a first dose of a pharmaceutical composition comprising a fumarate agent (e.g., DIVEF) for a first dosing period; (b) administering a vaccine; and (c) administering to the subject a second dose of the pharmaceutical composition for a second dosing period.
Abstract: The present invention provides antibodies and antigen-binding molecules thereof which specifically bind the ? and/or ? subunits of the non-active form of the GPIIb/IIIIa receptor. The antibodies and antigen-binding molecules can be genetically fused and/or conjugated to heterologous moieties and used, for example, as targeting moieties. The invention also includes methods for screening for these antibodies, as well as methods of making and methods of using chimeric molecules derived from the antibodies.
Abstract: A metering device that improves the aseptic transfer of powder and reconstitution fluid into the metering device for medical use. In some implementations, the metering device comprises a housing, containing a metering chamber that defines a volume. The housing also has a connection portion, an extraction portion, and a metering member in fluid communication with the metering chamber. In other embodiments, the metering device additionally includes a dispensing aid that facilitates the dispensing of powder from a first container into the metering chamber through the connection portion. The connection portion is capable of insertion into a second container that contains fluid, thereby allowing a mixture of powder and fluid to form in the metering chamber. The mixture, then ready for use, is removable from the metering chamber through the extraction portion by an extraction device.
Abstract: Various embodiments of medical detector systems as well as their methods of operation are disclosed. In one embodiment, one or more detectors are coupled to wearable structures for detecting at least a first tracer within a body portion. In another embodiment, one or more detectors are coupled to a wearable structure, where the detector corresponds to a CMOS chip that directly detects a first radioactive tracer.
Type:
Application
Filed:
December 21, 2018
Publication date:
July 4, 2019
Applicant:
Biogen MA Inc.
Inventors:
Ajay Verma, Marisa J. Bober, Victoria Cabot, Courtney D. Hilliard, Ara N. Knaian, Seth O. Newburg, John William Hoppin, Karl F. Schmidt
Abstract: The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds of formula I, and methods of using the compounds, salts and compositions in the treatment of various disorders associated with CRM1 activity.
Abstract: Antibodies that specifically bind to VLA-1 integrin and methods of using these antibodies to treat immunological disorders in a subject. Also included are crystal structures of complexes formed by VLA-1 antibodies and their ligands, and VLA-1 antagonists and agonists identified by using the structure coordinates of these structures.
Type:
Grant
Filed:
March 27, 2017
Date of Patent:
July 2, 2019
Assignee:
Biogen MA Inc.
Inventors:
Michael Karpusas, Paul D. Lyne, Ellen A. Garber Stark, Jose William Saldanha
Abstract: Methods of treating a subject having a condition characterized by at least one of neurodegeneration and neuroin-flammation are provided. Methods of reducing astrogliosis in a subject having a condition characterized by increased astrogliosis are also provided. Methods of providing neuroprotection to a subject in need thereof are also provided.
Abstract: The invention provided herein includes isolated polypeptides that specifically block the interaction between neonatal Fc receptor (FcRn) and albumin. Blocking the interaction treats diseases and conditions caused by increased amounts of albumin or modified albumin that possesses pathogenic properties wherein it is deemed desirable to decrease albumin levels. Accordingly, also provided are methods of using these isolated polypeptides to treat various diseases and conditions caused by increased amounts of albumin or modified albumin that possesses pathogenic properties. The invention provided herein also includes isolated polypeptides capable of binding to a non-IgG and non-albumin competitive site on an FcRn alpha 3 domain. These can be useful for tracking FcRn without inhibiting IgG or albumin binding or function. Accordingly, the invention also includes methods and systems to track FcRn without inhibiting IgG or albumin binding or function.
Type:
Application
Filed:
July 9, 2018
Publication date:
June 20, 2019
Applicants:
THE BRIGHAM AND WOMEN'S HOSPITAL, INC., BIOGEN MA INC.
Inventors:
Richard S. BLUMBERG, Timo RATH, Kristi BAKER, Adam MEZO, Zachary TAYLOR, Kevin MCDONNELL, Rosa Maria Silva Garcia GRENHA
Abstract: Aspects of the invention provide therapeutic recombinant protein preparations and methods of preparing therapeutic recombinant protein, which methods include contacting recombinant protein preparations with zwitterionic detergent at or above critical micelle concentration of the detergent.
Abstract: Provided are novel human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively.
Type:
Application
Filed:
June 27, 2018
Publication date:
June 6, 2019
Applicants:
Biogen MA Inc., Biogen International Neuroscience GmbH
Inventors:
Paul H. Weinreb, Feng Chen, Ellen A. Garber Stark, Jan Grimm, Fabio Montrasio
Abstract: The present invention pertains to methods of preventing and eliminating trisulfide bonds in proteins such as antibodies. In one embodiment, trisulfide bonds in proteins are converted to disulfide bonds as part of chromatographic purification procedures. In another embodiment, the formation of trisulfide bonds in proteins is inhibited by implementation of methods described herein during the cell culture production of such proteins. In another embodiment, monoclonal antibodies are produced by the methods described herein.
Type:
Grant
Filed:
March 4, 2015
Date of Patent:
June 4, 2019
Assignee:
Biogen MA Inc.
Inventors:
David Evans, R. Blake Pepinsky, Dingyi Wen, Rashmi Rohit Kshirsagar, Karin Lucas
Abstract: Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-Sp35 antibody.
Type:
Application
Filed:
June 26, 2018
Publication date:
May 30, 2019
Applicant:
Biogen MA Inc.
Inventors:
Sha Mi, R. Blake Pepinsky, Zhaohui Shao, Ellen A. Garber Stark, Steven D. Miklasz, Christilyn Graff
Abstract: This invention provides antibodies that recognize the B Cell Maturation Antigen (BCMA) and that bind naïve B cells, plasma cells, and/or memory B cells. The invention further provides methods for depleting naïve B cells, plasma cells, and memory B cells, and for treating B cell-related disorders, including lymphomas and autoimmune diseases.
Abstract: Methods and apparatus for assaying the level of analytes in a sample, related to VLA-4, are disclosed. A method of decreasing the level of an anti-integrin antibody in a subject is described including a) contacting a biological sample from a subject with a detectable capture agent associated with a substrate, wherein the capture agent can bind an anti-integrin antibody in the sample; b) detecting binding of the capture agent with the level of the anti-integrin antibody; and c) treating the subject with plasma exchange until the level of the anti-integrin antibody in the sample reaches a predetermined level.
Type:
Grant
Filed:
June 29, 2017
Date of Patent:
May 28, 2019
Assignee:
BIOGEN MA INC.
Inventors:
Tatiana Plavina, Paula S. Hochman, Michaela Lerner
Abstract: Various aspects and embodiments of the present disclosure relate to the purification antibodies by hydrophobic interaction chromatography under no-salt conditions.